公开(公告)号：US20150252345A1

公开(公告)日：2015-09-10

申请号：US14430848

申请日：2013-09-25

Applicant: BIOGEN IDEC MA INC.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang ,  Mark Brader

IPC: C12N9/64

CPC classification number: C12N9/644 ,  A61K38/00 ,  C07K14/745 ,  C07K16/36 ,  C07K2317/76 ,  C07K2319/30 ,  C12Y304/21022

Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.

Abstract translation: 本发明提供了施用长效因子IX的方法; 施用包含因子IX的长效，嵌合和杂合多肽的方法; 以及使用细胞产生这种嵌合和杂交多肽的方法。

公开(公告)号：US20150266944A1

公开(公告)日：2015-09-24

申请号：US14439435

申请日：2013-10-30

Applicant: BIOGEN IDEC MA INC.

Inventor： Haiyan Jiang ,  Srividya Neelakantan ,  Ivan Nestorov ,  Shuanglian Li

IPC: C07K14/755

CPC classification number: C07K14/755 ,  A61K38/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: The present invention provides methods of reducing or decreasing the annualized bleeding rate of a human subject having hemophilia by administering a long acting Factor VIII polypeptide. The long-acting FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia. The present invention relates generally to the field of therapeutics for hemostatic disorders.

Abstract translation: 本发明提供通过施用长效因子VIII多肽来降低或降低具有血友病的人类受试者的年化出血率的方法。 长效FVIII多肽可用于个体预防，每周预防，发作（按需）治疗或血友病围手术期管理。 本发明一般涉及止血障碍治疗领域。

公开(公告)号：US20150023959A1

公开(公告)日：2015-01-22

申请号：US14371948

申请日：2013-01-12

Applicant: BIOGEN IDEC MA INC.

Inventor： Ekta Seth Chhabra ,  Tongyao Liu ,  Robert T. Peters ,  Haiyan Jiang

IPC: C07K14/755 ,  C07K16/00

CPC classification number: C07K14/755 ,  A61K38/37 ,  A61K47/62 ,  C07K16/00 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/31

Abstract: The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

Abstract translation: 本发明提供了包含VWF的D'结构域和D3结构域的VWF片段，包含VWF片段和异源部分的嵌合蛋白质，或包含VWF片段和FVIII蛋白质的嵌合蛋白质及其使用方法。 包含本发明的VWF片段的多肽链与包含FVIII蛋白的多肽链结合或相关联，并且包含VWF片段的多肽链可以预防或抑制内源性VWF与FVIII蛋白的结合。 通过预防或抑制内源性VWF与作为FVIII的半衰期限制因子的FVIII的结合，VWF片段可诱导FVIII蛋白的半衰期延长。 本发明还包括核苷酸，载体，宿主细胞，使用VWF片段或嵌合蛋白的方法。

公开(公告)号：US20140370035A1

公开(公告)日：2014-12-18

申请号：US14371931

申请日：2013-01-12

Applicant: Biogen Idec MA Inc. ,  Puget Sound Blood Center

Inventor： Haiyan Jiang ,  Tongyao Liu ,  Sriram Krishnamoorthy ,  Neil Josephson ,  Glenn Pierce

IPC: A61K47/48 ,  C12Q1/68 ,  A61K38/37

CPC classification number: C12Q1/6883 ,  A61K38/21 ,  A61K38/37 ,  A61K39/0008 ,  A61K47/6811 ,  A61K47/6815 ,  A61K2039/6031 ,  A61K2039/6056 ,  C07K14/755 ,  C07K2319/30 ,  C12Q2600/156 ,  A61K2300/00

Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Abstract translation: 本公开提供了将具有FVIII和Fc的嵌合和杂合因子VIII（FVIII）多肽施用于具有发展抑制性FVIII免疫应答风险的受试者的方法，所述风险包括抗FVIII抗体和/或细胞介导的免疫。 该施用足以促进凝血并诱导对FVIII的免疫耐受。 嵌合多肽可以包含全长FVIII或含有缺失的FVIII多肽，例如B结构域的完整或部分缺失。